These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 29953178)
1. Parkinson’s Disease: Basic knowledge. Rose O Med Monatsschr Pharm; 2016 Jul; 39(7):277-81. PubMed ID: 29953178 [TBL] [Abstract][Full Text] [Related]
2. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033 [TBL] [Abstract][Full Text] [Related]
3. Overview of Parkinson's disease. Lew M Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935 [TBL] [Abstract][Full Text] [Related]
4. Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism. Tohgi H; Takahashi S; Abe T; Utsugisawa K Eur Neurol; 2001; 46(1):1-10. PubMed ID: 11455176 [TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and therapy of Parkinson's disease]. Wittstock M; Benecke R MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Parkinson's disease: present and future. Miller DB; O'Callaghan JP Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818 [TBL] [Abstract][Full Text] [Related]
8. [A 78-year-old man with young onset parkinsonism and sudden death]. Miyasaka H; Mori H; Saikawa T; Shirai T; Kondo T; Imai H; Mizuno Y No To Shinkei; 1996 May; 48(5):487-95. PubMed ID: 8672309 [TBL] [Abstract][Full Text] [Related]
9. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. Hill WD; Arai M; Cohen JA; Trojanowski JQ J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049 [TBL] [Abstract][Full Text] [Related]
10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
12. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday. Lees AJ Mov Disord; 2007 Sep; 22 Suppl 17():S327-34. PubMed ID: 18175393 [TBL] [Abstract][Full Text] [Related]
17. The use of PET in Parkinson's disease. Shinotoh H; Calne DB Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856 [TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease. Béné R; Antić S; Budisić M; Lisak M; Trkanjec Z; Demarin V; Podobnik-Sarkanji S Acta Clin Croat; 2009 Sep; 48(3):377-80. PubMed ID: 20055267 [TBL] [Abstract][Full Text] [Related]
19. Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. Vecchia DD; Kanazawa LKS; Wendler E; de Almeida Soares Hocayen P; Bruginski E; Campos FR; Stern CAJ; Vital MABF; Miyoshi E; Wöhr M; Schwarting RKW; Andreatini R Behav Brain Res; 2018 Apr; 342():1-10. PubMed ID: 29307665 [TBL] [Abstract][Full Text] [Related]